A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 394 participants.
Also called NCT01513590
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 394 participants
- Sponsor
- Registry
-
NCT01513590 -
2011-001712-61
-
- Other papers using this trial's data
- Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Algeria, Bulgaria, Croatia, Czechia, Germany, Poland, Romania, Slovakia, Türkiye, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01513590. Randomized; no masking; primary purpose treatment. Start 2012-01-16 (actual); primary completion 2012-11-19 (actual). Results posted on 2015-11-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes
- Acronym
- BOOST™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/insulin aspart
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01513590- Content hash
3ac70eeac472efe15621b465bd77c755bd19cc2b4f74f62969801f5f442ae359